Pharmaceuticals

Envirotainer launches the Releye® RLP - simpler than passive, even better than active

STOCKHOLM, May 6, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today launched their latest innovation, the Releye® RLP, a temperature-controlled air freight container with a revolutionary new footprint, unsur...

2021-05-06 02:20 178

Yangtze River Pharmaceutical Group Selects TraceLink Platform for Global Compliance

NORTH READING, Mass., May 5, 2021 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international...

2021-05-05 20:00 468

CSafe Global Providing Thermal Protection for COVID-19 Vaccine Shipments from BioNTech Facility

The tailor-made double-wall VIP insulated shipper provides 10+ days of temperature protection for vaccine shipments from BioNTech's facility with minimal dry ice. DAYTON, Ohio, May 5, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in active, passive parcel and cell and gene temperature...

2021-05-05 20:00 534

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study

China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory di...

2021-05-03 20:30 2393

BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with BioElpida S.A.S. ("BioElpida") of Lyon,Franc...

2021-05-03 20:00 1481

Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer is Expected to Alleviate the Oxygen Shortage Crisis during COVID-19 Pandemic

SHANGHAI, May 1, 2021 /PRNewswire/ -- In June, 2020, an academic paper on patients with COVID-19 inhaling hydrogen oxygen mixed gas produced by Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer was published in the Journal of Thoracic Disease. The multicenter, and open-label clinical t...

2021-05-01 17:17 2128

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic

Commercial trademark application FILED for CoviDTH® diagnostic cancer vaccine platform patent coverageexpanded to NOW include over 12 tumor types VANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world ...

2021-04-29 20:56 1641

Hilco Industrial Acquires All Machinery & Equipment from Legacy Pharmaceutical Switzerland

BASEL, Switzerland, April 29, 2021 /PRNewswire/ -- Hilco Industrial Acquisitions, anAmsterdam-based Industrial Asset Disposition and Acquisition Company, acquired all Machinery & Equipment from theSwiss-based CMO Legacy Pharmaceuticals. After several years of expansion, the Swiss company was forc...

2021-04-29 13:04 875

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)

SUZHOU, China, April 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the efficacy and safety of KN046 in combination with Inlyta® (axitinib) for the first-line treatment ...

2021-04-29 08:00 3146

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2021-04-29 08:00 2611

AnchorDx Jointly Publishes Clinical Research Paper: "Accurate Diagnosis of Pulmonary Nodules Using a Non-invasive DNA Methylation Test"

GUANGZHOU, China, April 28, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned thoracic experts from 14 top-tier hospitals inChina, jointly published a clinical research paper entitled "Accurate Diagnosis of Pulmonary...

2021-04-28 21:00 778

Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2

- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...

2021-04-28 20:00 714

CROs dMed and Clinipace Merge to Accelerate Customer Success

SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...

2021-04-28 20:00 1158

Hovid Berhad Partners with Esker to Automate its Accounts Payable Process

SINGAPORE, April 27, 2021 /PRNewswire/ -- Esker , a globalcloud platform  and leader inAI-driven process automation solutions  for finance and customer se...

2021-04-27 09:35 871

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...

2021-04-27 09:23 1410

Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer

SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-26 22:08 994

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients

SUZHOU, China, April 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration ...

2021-04-26 21:14 1655

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...

2021-04-23 20:00 2785

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

STOCKHOLM, April 23, 2021 /PRNewswire/ -- Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health mark...

2021-04-23 15:22 1165

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-23 15:00 1017
12345 ... 107